Amanda R Kreider1, Meredith Matone1, Christopher Bellonci2, Susan dosReis3, Chris Feudtner4, Yuan-Shung Huang5, Russell Localio6, David M Rubin7. 1. PolicyLab at the Children's Hospital of Philadelphia. 2. Tufts University School of Medicine. 3. Department of Pharmaceutical Health Services Research at the University of Maryland School of Pharmacy. 4. PolicyLab at the Children's Hospital of Philadelphia, the Department of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, and the Division of General Pediatrics at the Children's Hospital of Philadelphia. 5. Division of General Pediatrics at the Children's Hospital of Philadelphia. 6. Department of Biostatistics and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania. 7. PolicyLab at the Children's Hospital of Philadelphia, the Department of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, and the Division of General Pediatrics at the Children's Hospital of Philadelphia. Electronic address: rubin@email.chop.edu.
Abstract
OBJECTIVE: Second-generation antipsychotics (SGAs) have increasingly been prescribed to Medicaid-enrolled children; however, there is limited understanding of the frequency of concurrent SGA prescribing with other psychotropic medications. This study describes the epidemiology of concurrent SGA use with 4 psychotropic classes (stimulants, antidepressants, mood stabilizers, and α-agonists) among a national sample of Medicaid-enrolled children and adolescents 6 to 18 years old between 2004 and 2008. METHOD: Repeated cross-sectional design was used, with national Medicaid Analytic eXtract data (10.6 million children annually). Logit and Poisson regression, standardized for year, demographics, and Medicaid eligibility group, estimated the probability and duration of concurrent SGA use with each medication class over time and examined concurrent SGAs in relation to clinical and demographic characteristics. RESULTS: While SGA use overall increased by 22%, 85% of such use occurred concurrently. By 2008, the probability of concurrent SGA use ranged from 0.22 for stimulant users to 0.52 for mood stabilizer users. Concurrent SGA use occurred for long durations (69%-89% of annual medication days). Although the highest users of concurrent SGA were participants in foster care and disability Medicaid programs or those with behavioral hospitalizations, the most significant increases over time occurred among participants who were income-eligible for Medicaid (+13%), without comorbid ADHD (+15%), were not hospitalized (+13%), and did not have comorbid intellectual disability (+45%). CONCLUSION: Concurrent SGA use with other psychotropic classes increased over time, and the duration of concurrent therapy was consistently long term. Concurrent SGA regimens will require further research to determine efficacy and potential drug-drug interactions, given a practice trend toward more complex regimens in less-impaired children/adolescents.
OBJECTIVE: Second-generation antipsychotics (SGAs) have increasingly been prescribed to Medicaid-enrolled children; however, there is limited understanding of the frequency of concurrent SGA prescribing with other psychotropic medications. This study describes the epidemiology of concurrent SGA use with 4 psychotropic classes (stimulants, antidepressants, mood stabilizers, and α-agonists) among a national sample of Medicaid-enrolled children and adolescents 6 to 18 years old between 2004 and 2008. METHOD: Repeated cross-sectional design was used, with national Medicaid Analytic eXtract data (10.6 million children annually). Logit and Poisson regression, standardized for year, demographics, and Medicaid eligibility group, estimated the probability and duration of concurrent SGA use with each medication class over time and examined concurrent SGAs in relation to clinical and demographic characteristics. RESULTS: While SGA use overall increased by 22%, 85% of such use occurred concurrently. By 2008, the probability of concurrent SGA use ranged from 0.22 for stimulant users to 0.52 for mood stabilizer users. Concurrent SGA use occurred for long durations (69%-89% of annual medication days). Although the highest users of concurrent SGA were participants in foster care and disability Medicaid programs or those with behavioral hospitalizations, the most significant increases over time occurred among participants who were income-eligible for Medicaid (+13%), without comorbid ADHD (+15%), were not hospitalized (+13%), and did not have comorbid intellectual disability (+45%). CONCLUSION: Concurrent SGA use with other psychotropic classes increased over time, and the duration of concurrent therapy was consistently long term. Concurrent SGA regimens will require further research to determine efficacy and potential drug-drug interactions, given a practice trend toward more complex regimens in less-impaired children/adolescents.
Authors: James G Waxmonsky; Daniel A Waschbusch; Peter Belin; Tan Li; Lysett Babocsai; Hugh Humphery; Meaghan E Pariseau; Dara E Babinski; Martin T Hoffman; Jenifer L Haak; Jessica R Mazzant; Gregory A Fabiano; Jeremy W Pettit; Negar Fallahazad; William E Pelham Journal: J Am Acad Child Adolesc Psychiatry Date: 2015-12-28 Impact factor: 8.829
Authors: Rebecca P Barclay; Robert B Penfold; Donna Sullivan; Lauren Boydston; Julia Wignall; Robert J Hilt Journal: Health Serv Res Date: 2017-04 Impact factor: 3.402
Authors: Chad E Shenk; Brooks Keeshin; Heather E Bensman; Anneke E Olson; Brian Allen Journal: Pharmacol Biochem Behav Date: 2021-11-10 Impact factor: 3.533
Authors: Raman Baweja; Peter J Belin; Hugh H Humphrey; Lysett Babocsai; Meaghan E Pariseau; Daniel A Waschbusch; Martin T Hoffman; Opeolowa O Akinnusi; Jenifer L Haak; William E Pelham; James G Waxmonsky Journal: J Child Adolesc Psychopharmacol Date: 2016-01-15 Impact factor: 2.576